Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Stomach Neoplasms

Esophageal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Head and Neck Neoplasms

Esophageal Diseases

Stomach Cancer

Esophageal Cancer

All Drugs and Chemicals

Immunomodulating Agents

Immunologic Factors

Surgery

Chemotherapy, anti-targeted agents and immunotherapy

Radiotherapy

Paula Dr Jiménez Fonseca, MD-PhD

Paula Dr Jimenez Fonseca, MD-PhD

This study aims to development of a database through a web page for epidemiological and clinical research purposes that is accessible to members of the AGAMENON - SEOM group that guarantees a rigorous collection, exploitation and analysis of the data and information contained, increases the knowledge of esophageal and stomach cancer in order to optimize the management, treatment and evolution of patients, the possibility of comparing variables with those of other series or groups, and promotes the quality of scientific publications.

Patient data will be collected from medical records retrospectively.

Spanish Registry of Esophagogastric Cancer

AGAMENON-SEOM Study: Spanish Registry of Esophagogastric Cancer

To evaluate survival (time in months) according to treatment of esophagogastric cancer in all stages, patients, and contexts.

To know the epidemiological profiles of esophagogastric cancer in Spain: temporal and regional trends, morbidity, and mortality.

To study risk factors associated with each subtype of esophagogastric cancer and localization.

To evaluate the pathological features (TNM, grade, histological response)

The TNM is measured with the American Joint Committee on Cancer (AJCC) staging system.

The grade is classified with the WHO scale. Histological response is measured with Becker classification.

To know the diagnostic approch according to the center, type of studies performed: endoscopy, CT, echoendoscopy and/or PET/CT.

From these studies it will be collected whether they have been carried out and where they visualise tumour. The use of scales and measurements is therefore not appropriate.

To compare treatments adjusted to prognostic variables and baseline characteristics.

To validate and compare the three prognostic models for advanced esophagogastric adenocarcinoma: The Royal Marsden Hospital index (Chau et al, 2004), and the models of Kim (2008) and Lee (2007), in a real sample of patients based on daily clinical practice.

To analyze the prognostic factors in this population and build a predictive and/or prognostic model.

To create and validate a predictive model of early mortality.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Spanish Registry of Esophagogastric Cancer	NCT04958720	Esophageal Canc... Gastric Cancer	Surgery Chemotherapy, a... Radiotherapy	18 Years - 100 Years	Fundación Sociedad Española de Oncologia Médica
Spanish Registry of Esophagogastric Cancer	NCT04958720	Esophageal Canc... Gastric Cancer	Surgery Chemotherapy, a... Radiotherapy	18 Years - 100 Years	Fundación Sociedad Española de Oncologia Médica

Spots Global Cancer Trial Database for antitargeted drug